PTO/SB/81 (04-05)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control and the business. Under the Paperwork Reduction Act of 1995, no persons are requir

## **POWER OF ATTORNEY** and **CORRESPONDENCE ADDRESS INDICATION FORM**

Application Number	ormation unless it displays a valid Olvis control number.
Filing Date	March 28, 2006
First Named Inventor	Amanda Proudfoot
Title	Therapeutic Uses of Chemokine
Art Unit	
Examiner Name	
Attorney Docket Number	ARS-124

I hereby royoke a	II previo	ous powers of attorney give	von in the al	ove ide	ntified applic	ration		
I hereby appoint:	ii previc			30VE-10E	milied applic	alion.	· · · · · · · · · · · · · · · · · · ·	
Thereby appoint.								
✓ Practitioners as	sociated	with the Customer Number:		23557				
OR								
Practitioner(s)	named be	elow:						
		Name			Registra	tion Numbe	er	
		<del></del>						
		·						
		<del>-</del>				•		
		-> 4						ı
Trademark Office con	or agent( nected th	s) to prosecute the application erewith.	identified above	e, and to t	ransact all busir	iess in the	United States Patent and	ı
Diagon recognize or o	honno the		ha ahawa idaat	:C.d!	41 4			
	nange me	e correspondence address for t	ne above-ident	illeu appili	cation to:			
The address	associat	ed with the above-mentioned C	ustomer Numb	er:		_		
					•			
The address associated with Customer Number:								
OR Firm or		<u> </u>						
Individual	Name							
Address						•		
<u>.</u> .								
City				State		·	Zip	
Country				I == '11 ]				
Telephone				Email	-			
I am the:	ontor							
L▼								
		the entire interest. See 37 CFR FR 3.73(b) is enclosed. (Form						
	**	SIGNATURE of		ssignee	of Record		<del> </del>	
Signature	<u> </u>	<del></del>		*	•	Date	<del></del>	
Name	AMAND	A PROUDFOOT		<del></del>		Telephone	<del></del>	
Title and Company						Тогористо		
NOTE: Signatures of all t		rs or assignees of record of the enti	re interest or thei	r represent	ative(s) are require	ed. Submit m	nultiple forms if more than on	
signature is required, see	below*.		<del></del>	····				
Total of		forms are submitted.						

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are require

## **POWER OF ATTORNEY** and **CORRESPONDENCE ADDRESS INDICATION FORM**

U.S. Patent and To	PTO/SB/81 (04-05) Approved for use through 11/30/2005. OMB 0651-0035 rademark Office; U.S. DEPARTMENT OF COMMERCE
red to respond to a collection of info Application Number	ormation unless it displays a valid OMB control number.
Filing Date	<u> </u>
	March 28, 2006
First Named Inventor	Amanda Proudfoot
Title	Therapeutic Uses of Chemokine
Art Unit	
Examiner Name	
Attorney Docket Number	ARS-124

I hereby revoke a	II previo	ous powers of attorney gi	ven in the a	above-ide	entified applic	ation.			
I hereby appoint:									
	Practitioners associated with the Customer Number:			235	557				
OR		'							
Practitioner(s)	named be	elow:							
	••	Name			Registra	tion Numbe	er		
		·				<del></del>		-	ł
				•					l
	<del></del>	-							
as my/our attorney(s)	or agent(	s) to prosecute the application	identified abo	ve. and to t	ransact all busin	ess in the	United	States Patent an	i d
Trademark Office con									
Please recognize or c	hange the	e correspondence address for t	the above-ide	ntified applic	cation to:				
The address	associat	ed with the above-mentioned C	Customer Num	nber:					
OR									
The address associated with Customer Number:									
OR	OR								
Firm or Individual Name									
Address									
City				State			Zip		
Country									
Telephone		l <u></u>		Email					
l am the:  Applicant/Inventor.									
		the entire interest. See 37 CFF FR 3.73(b) is enclosed. (Form							
		SIGNATURE of	Applicant or	Assignee	of Record				
Signature						Date			
Name	JEFFRE	Y SHAW				Telephone			
Title and Company			-						
NOTE: Signatures of all signature is required, see		rs or assignees of record of the ent	ire interest or th	eir represent	ative(s) are require	ed. Submit m	nultiple (	forms if more than o	ne
Total of		forms are submitted.							

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/81 (04-05)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
O a collection of information unless it displays a said ONP control part of the control part of Under the Paperwork Reduction Act of 1995, no persons are require

## **POWER OF ATTORNEY** and **CORRESPONDENCE ADDRESS INDICATION FORM**

red to respond to a collection of init	rmation unless it displays a valid OMB control number	er.
Application Number		1
Filing Date	March 28, 2006	
First Named Inventor	Amanda Proudfoot	_
Title	Therapeutic Uses of Chemokine	_
Art Unit		
Examiner Name		_
Attorney Docket Number	ARS-124	

I hereby revoke a	II previo	ous powers of attorney give	ven in the ab	ove-ide	entified applic	ation.		
I hereby appoint:								
✓ Practitioners a	ssociated with the Customer Number: 23557							
OR		l						
Practitioner(s)	named be	low:						
		Name			Registra	tion Numbe	r	
							<del></del>	
as my/our attorney(s) Trademark Office cor		s) to prosecute the application erewith.	identified above	, and to t	ransact all busir	ess in the l	United States Patent and	l
Please recognize or o	hange the	e correspondence address for t	the above-identi	fied appli	cation to:			
The address	s associat	ed with the above-mentioned C	Sustamer Numbe	er.				
OR	address associated with the above-mentioned Customer Number:							
The address	The address associated with Customer Number:							
OR								
Firm or Individua	l Name							
Address								
City	_			State		j	Zip	
Telephone				Email				
I <u>am</u> the:								
Applicant/Inventor.								
Assignee of record of the entire interest. See 37 CFR 3.71.  Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)								
		SIGNATURE of		ssignee	of Record		· · · · · · · · · · · · · · · · · · ·	-
Signature						Date		
Name	ZOE JO	HNSON				Telephone		
Title and Company								
NOTE: Signatures of all signature is required, se		rs or assignees of record of the enti	ire interest or their	represent	ative(s) are require	ed. Submit m	ultiple forms if more than on	e
*Total of		forms are submitted.						

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

## DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	THERAPEUTIC USES OF CHEMOKINE VARIANTS			
As the belo	w named inventor(s), I/we declare that:			
This declar	ation is directed to:			
	The attached application, or			
	Application No. PCT/EP2004/052572 , filed on October 18, 2004 ,			
	as amended on(if applicable);			
I/we believe sought;	that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is			
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any a specifically referred to above;			
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.				
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.				
FULL NAMI	E OF INVENTOR(S)			
	e: _AMANDA PROUDFOOT			
	Citizen of: SWITZERLAND			
Inventor two	o: _JEFFREY SHAW			
Signature: _	Citizen of:			
Inventor thr	ee: ZOE JOHNSON			
Signature: _	Citizen of: UNITED KINGDOM			
Inventor fou	r:			
Signature: _	Citizen of:			
Additi	onal inventors or a legal representative are being named on additional form(s) attached hereto.			

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.